Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Date:12/15/2008

alidated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about APD597's development, therapeutic indication, efficacy and potential; the potential of the GDIR, including the potential to stimulate insulin release in response to increases in blood glucose; future activities under Arena's collaboration with Ortho-McNeil; the protocol, design, scope, enrollment and other aspects of the Phase 1 program for APD597; the inclusion of the evaluation of patients with type 2 diabetes in the planned clinical studies; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents an
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 According ... (Surface & Intravascular Systems- Warming & Cooling), Application ... (Surgeon & Anesthesiologist, Nursing & Paramedical Staff) - ... MarketsandMarkets, this report studies the global Temperature Management Market ... The market is expected to reach $2.5 Billion ...
(Date:9/18/2014)... SAN ANTONIO, Texas , Sept. 18, 2014  Casen ... vessels, skin and muscles to harden.  His case is one ... (GVM) in the world.  The only hospital in ... few in the world, offering treatment with the dual wave-length ... in San Antonio . Using a laser ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "China PTCA Balloon Market Investment Report, 2014-2016" ... as a indispensable medical device in percutaneous coronary intervention ... stent, but also as a device for pre-/post-stent dilatations. ... related to that of PCI. As national ...
Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3
... Medical Systems, a global developer of high-end ultrasound systems, ... number of clinical applications and ranked first or second ... KLAS  "Ultrasound 2011: Innovation on the Move" report. ... monitoring and reporting the performance of information technology and ...
... Suneva Medical, a privately-held aesthetic medical device ... aesthetics injectable business with approval from Health Canada ... dermal filler for nasolabial folds or smile line ... long-lasting treatment, Bellafill provides physicians the opportunity to ...
Cached Medicine Technology:ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 2ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 3Suneva Medical Announces Canadian Approval of Bellafill™ 2
(Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. ... that testosterone replacement therapy effectively treats normally sagging levels of ... Drug Administration advisory panel said Wednesday. The panel, from ... of the popular drugs and require drug makers to conduct ... according to Bloomberg News . "The whole idea ...
(Date:9/18/2014)... led by Queen,s University professor Robert Campbell (Ophthalmology) has ... not helpful or necessary., Glaucoma is the most common ... 400,000 Canadians are afflicted with the disease, which is ... enough to damage the optic nerve. The optic nerve ... the brain and is a vital part of vision., ...
(Date:9/18/2014)... In ecology, disease tolerance is ... and nail, but rather tolerate it to live (and survive) better ... the disease only progresses very slowly if at all ... Regoes, a senior scientist at ETH Zurich,s Institute of Theoretical Biology, ... whether there are infected people who are more tolerant of the ...
(Date:9/18/2014)... It is almost time to park your ... healthier and happier kids. The South Florida Hyundai Dealers ... Annual Miami Children’s Hospital 5K Run/Walk. Its title sponsor ... , The 5K will take place on Saturday August 20th. ... Coral Gables City Hall located at 405 Biltmore Way. ...
(Date:9/18/2014)... Pittsburgh, PA (PRWEB) September 18, 2014 ... oncologists from Allegheny Health Network has documented ... undergo both surgical removal of the tumors along with ... annual meeting of ASTRO (American Society for ... radiosurgery (SRS) uses numerous precisely focused radiation beams to ...
Breaking Medicine News(10 mins):Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3
... , ATLANTA, Aug. 6 ... the launch of an Atlanta-based program aimed at improving ... Emory University,s Latino Diabetes Education Program and the Johnson ... diabetes education in Hispanic and African American populations and ...
... , , MOUNTAIN ... MAPP ) announced today the pricing of its previously announced public ... offering price of $9.70 per share. Net proceeds, after estimated underwriting ... MAP Pharmaceuticals has granted the underwriters of the offering a ...
... , , , ... Inc. (OTC Bulletin Board: CCEL), one of the largest and most ... proliferative ability of stem cells found in menstrual blood (known as ... Dalian, China. Data from an in vitro study show that MenSCs ...
... Puerto Ricans, Mexicans, study finds , WEDNESDAY, Aug. 5 (HealthDay ... the good life comes at a price: A new study ... , Living the American lifestyle is probably to blame, say ... , Of three Hispanic subgroups they studied -- Puerto Ricans, ...
... , ST. LOUIS, Aug. 6 ... improvement and cost savings results of the IMI program at ... Association (AHA) Leadership Summit. Kirk Mathews, CEO of IMI, and ... average three-month-trend results of $1,500 Cost-per-Case reduction as well as ...
... TAMPA, Fla., Aug. 6 Gold Standard/Elsevier ... launch of three MedCounselor consumer drug information modules for pharmacies ... how to take medications safely, assists in identifying unknown tablets ... are indispensable in helping to increase consumer compliance to their ...
Cached Medicine News:Health News:AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes 2Health News:AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes 3Health News:AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes 4Health News:MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock 2Health News:MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock 3Health News:Cryo-Cell to Present Novel Adult Stem Cell Research During 2009 China Medical Biotech Forum 2Health News:Cryo-Cell to Present Novel Adult Stem Cell Research During 2009 China Medical Biotech Forum 3Health News:Cryo-Cell to Present Novel Adult Stem Cell Research During 2009 China Medical Biotech Forum 4Health News:Living in U.S. May Raise Hispanics' Cancer Risk 2Health News:Living in U.S. May Raise Hispanics' Cancer Risk 3Health News:Inpatient Management, Inc. and Reid Hospital Achieve Performance Improvement and Cost Savings 2Health News:Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules 2Health News:Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules 3
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
Medicine Products: